Study wrapper · #243
Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.
Editor's note
A method-development paper for anti-doping testing, not a pharmacology study. The authors extended a single mass-spectrometry workflow to screen a broad panel of performance-relevant peptides (roughly 2–12 kDa) — including the GHRH analogues sermorelin, CJC-1293, CJC-1295, and tesamorelin, plus insulins, synthetic ACTH, IGF-I and mechano growth factors — from blood and urine. Tesamorelin and CJC-1295 appear only as analytical targets in a list; the proof-of-principle validation was actually done with insulins and Synacthen, not the GHRH analogues. Its contribution is throughput and breadth for testing labs, not any clinical insight. For readers, the relevance is contextual: these peptides are enough of a doping concern to warrant a combined screen. It offers nothing about efficacy, dosing, or safety of tesamorelin (FDA-approved only for HIV-associated lipodystrophy) or CJC-1295 (small Phase II human data only). Weight it as regulatory infrastructure.
Plain-language abstract
This paper describes a single laboratory test able to screen for many banned peptides at once, to make sports drug testing faster, broader, and cheaper. Bigger bioactive peptides (roughly 2 to 12 kilodaltons in size) are used to try to enhance performance and are hard to detect. The target list included growth-hormone-releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin), several synthetic and animal insulins, synthetic ACTH (Synacthen), synthetic IGF-I, and mechano growth factors. The method concentrated all the targets from a sample using ultrafiltration and antibody-coated magnetic beads, then separated and detected them with high-resolution mass spectrometry. It worked on both blood and urine — the most common testing samples — and was validated for specificity, recovery, and sensitivity, detecting substances at very low levels. The 'proof of principle' with real samples came from insulin degludec, detemir, aspart, and Synacthen. The study is purely about detecting these substances; it does not test whether any of them, including tesamorelin or CJC-1295, are effective or safe.